Guggenheim raised the firm’s price target on Insmed (INSM) to $230 from $227 and keeps a Buy rating on the shares. The firm adjusted estimates as part of a Q1 earnings preview for commercial-stage companies in its biotechnology coverage.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $216 from $212 at RBC Capital
- Insmed initiated with an Outperform at Raymond James
- Insmed price target lowered to $202 from $206 at Mizuho
- Reallocating Capital Beyond HS: Supporting a Buy Rating on Insmed’s Diversified Next‑Generation Pipeline
- Insmed price target lowered to $212 from $213 at BofA